secwatch.observer — SEC 8-K summary
======================================

Issuer:     biote Corp. (BTMD)
CIK:        0001819253
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196974
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biote Q2 revenue $49.2M, net loss narrows to $10.5M; procedure revenue grows 7.8% sequentially
--------------------------------------------------------------------------------

- Revenue of $49.2M; procedure revenue $38.4M, up 7.8% QoQ vs 6.6% in Q1.
- Net loss of $(10.5)M (EPS $(0.19)) improved from $(13.1)M ($(0.25)) in Q2 2023.
- Adjusted EBITDA of $12.7M; gross profit margin 68.9% with $1.2M inventory step-up from Asteria Health acquisition.
- New clinics grew ~30% in H1 2024; 2024 full-year financial guidance reaffirmed.
- BioteRx roll-out on track; management plans further geographic and therapeutic wellness expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819253/000119312524196974/0001193125-24-196974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819253/000119312524196974/d831251d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer